Healthcare Tech

Ever since Amazon launched its digital pharmacy late last year, industry rivals have been worried the tech giant would steal the show. Rather than waiting to find out, they’re all scrambling to secure their spot on the stage. Some, like Nurx and Folx, are zeroing in on underserved or specific populations, hoping to build a
0 Comments
On Wednesday, federal officials quietly opened up access to VaccineFinder, a site that allows the U.S. public to search nationwide for approved Covid-19 vaccine providers. On vaccinefinder.org, users can enter an address or ZIP code and select a search area — say, within 10 miles — and get a list of providers with contact information,
0 Comments
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Log In | Learn More What is it? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science
0 Comments
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Log In | Learn More What is it? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science
0 Comments
As the world charges to vaccinate the population against the coronavirus, gene therapy developers are locked in a counterintuitive race. Instead of training the immune system to recognize and combat a virus, they’re trying to do the opposite: designing viruses the body has never seen, and can’t fight back against. It’s OK, reallay: These are
0 Comments
The great hope of artificial intelligence in breast cancer is that it can distinguish harmless lesions from those likely to become malignant. By scanning millions of pixels, AI promises to help physicians find an answer for every patient far sooner, offering them freedom from anxiety or a better chance against a deadly disease. But the
0 Comments
A long-documented, under-the-radar disparity is garnering new attention as the Covid-19 pandemic stretches into another year: Some pulse oximeters, which measure oxygen levels and are critical to making decisions about patient care, aren’t as accurate in Black patients and other people of color. New research on the issue has drawn the attention of lawmakers and
0 Comments
A vanguard of virtual behavioral health startups are attracting investor interest. The latest: Equip, which provides online treatment for eating disorders, announced Wednesday it has raised a $13 million Series A round. The round was led by Optum Ventures. New investor .406 Ventures joined, as did F-Prime Capital, which led the company’s seed round. Total
0 Comments
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Log In | Learn More What is it? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science
0 Comments
The Biden administration’s recent investment of $230 million to expedite rapid production of the Ellume home Covid-19 test represents an audacious step forward in mitigating the pandemic. Some experts have criticized it as a “waste of money” because this kit costs more than other alternatives and because of the timing of the investment. I believe
0 Comments
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Log In | Learn More What is it? STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science
0 Comments
The genetics testing company 23andMe will enter the public markets via a special purpose acquisition corporation sponsored by Virgin Group founder Richard Branson, a deal that values the company at $3.5 billion. The transaction with VG Acquisition Corp. will provide a burst of capital to 23andMe as it seeks to expand its business beyond direct-to-consumer
0 Comments